Amgen has a total of 25065 patents globally, out of which 10783 have been granted. Of these 25065 patents, more than 50% patents are active. United States of America is where Amgen has filed the maximum number of patents, followed by Europe and Australia. Parallelly, USA seems to be the main focused R&D center and is also the origin country of Amgen.
Amgen was founded in 1980 by George Rathmann. Amgen is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses on human therapeutics and concentrates on innovating novel medicines based on cellular and molecular biology. As of March 2022, Amgen has a market cap of $129.74 Billion.
Do read about some of the most popular patents of Amgen which have been covered by us in this article and also you can find Amgen patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Amgen patent portfolio.
How many patents does the CEO of Amgen have?
The CEO, Robert A. Bradway have 1 patent.
How many patents does Amgen have?
Amgen has a total of 25065 patents globally. These patents belong to 3418 unique patent families. Out of 25065 patents, 12561 patents are active.
How many Amgen patents are Alive/Dead?
Worldwide Patents
How Many Patents did Amgen File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Amgen Applications Filed | Amgen Patents Granted |
| 2011 | 1094 | 545 |
| 2012 | 1292 | 590 |
| 2013 | 861 | 670 |
| 2014 | 1446 | 734 |
| 2015 | 918 | 527 |
| 2016 | 955 | 606 |
| 2017 | 842 | 658 |
| 2018 | 1219 | 613 |
| 2019 | 1237 | 637 |
| 2020 | 899 | 754 |
| 2021 | 554 | 786 |
| 2022 | 4 | 84 |
Which Amgen Drug Patents are Expiring in the Next 10 Years?
The patent no. US7737112B2 which is expiring in Dec, 2027, describing medication that improves conditions like neurodegenerative diseases, immune disorders, muscle wasting, cancer, chronic infections, fever, muscle disease, denervation, nerve injury, and fasting when given to a patient. The drug comprises a proteasome inhibitor that is practically insoluble, along with a cyclodextrin and optionally a buffer.
Given below is the list of few drugs patented by Amgen accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Kyprolis | US7737112B2 | Composition For Enzyme Inhibition | Dec, 2027 |
| Corlanor | US7867996B2 | γ-Crystalline Form Of Ivabradine Hcl… | Jun, 2027 |
| Parsabiv | US11162500B2 | Stable Liquid Formulation Of Amg… | Jun, 2034 |
| Sensipar | US7829595B2 | Rapid Dissolution Formulation Of… | Sep, 2026 |
| Otezla | US9872854B2 | Methods For The Treatment Of … | May, 2034 |
Interested in knowing about Amgen Drug Patents Expiring in the next 10 years?
How Many Patents did Amgen File in Different Countries?
Countries in which Amgen Filed Patents
| Country | Patents |
| United States Of America | 3493 |
| Europe | 1982 |
| Australia | 1836 |
| Japan | 1819 |
| Canada | 1192 |
| Mexico | 905 |
| Germany | 861 |
| Hong Kong (S.A.R.) | 753 |
| China | 702 |
| Israel | 686 |
| Spain | 654 |
| Korea (South) | 618 |
| Singapore | 617 |
| Taiwan | 485 |
| Brazil | 402 |
| Denmark | 400 |
| India | 380 |
| Argentina | 337 |
| Austria | 331 |
| Portugal | 322 |
| Eurasian Patent Organization | 310 |
| New Zealand | 307 |
| Chile | 296 |
| Poland | 266 |
| Malaysia | 241 |
| Slovenia | 236 |
| South Africa | 225 |
| Philippines | 190 |
| Peru | 177 |
| Costa Rica | 165 |
| Uruguay | 157 |
| Indonesia | 147 |
| Cyprus | 142 |
| Hungary | 137 |
| Serbia | 121 |
| Croatia | 116 |
| Norway | 115 |
| Viet Nam | 111 |
| Lithuania | 105 |
| Tunisia | 95 |
| Morocco | 95 |
| Ukraine | 84 |
| Russian Federation | 81 |
| Jordan | 64 |
| United Kingdom | 49 |
| Colombia | 47 |
| Montenegro | 47 |
| Czech Republic | 39 |
| Turkey | 32 |
| Slovakia | 27 |
| Bulgaria | 24 |
| Finland | 24 |
| Gulf Cooperation Council | 20 |
| Georgia | 20 |
| Luxembourg | 19 |
| Netherlands | 18 |
| Ecuador | 16 |
| San Marino | 16 |
| Iceland | 15 |
| Europe | 15 |
| Cuba | 12 |
| Dominican Republic | 12 |
| Uzbekistan | 12 |
| Ireland | 11 |
| Saudi Arabia | 10 |
| Thailand | 9 |
| Estonia | 9 |
| Macao | 8 |
| Botswana | 7 |
| Yugoslavia/Serbia and Montenegro | 7 |
| Honduras | 6 |
| Bolivia | 5 |
| Belarus | 5 |
| Mongolia | 5 |
| Brunei | 5 |
| African Regional Industrial Property Organization | 8 |
| Nicaragua | 4 |
| Romania | 4 |
| El Salvador | 3 |
| Egypt | 2 |
| Republic of Moldova | 2 |
| United Arab Emirates | 1 |
| Malta | 1 |
| Belize | 1 |
| Mozambique | 1 |
| Belgium | 1 |
| Greece | 1 |
| Guatemala | 1 |
| Kazakhstan | 1 |
Where are Research Centers of Amgen Patents Located?
10 Best Amgen Patents
WO2009089004A1 is the most popular patent in the Amgen portfolio. It has received 2544 citations so far from companies like Genentech Inc, Novartis and Roche Holding.
Below is the list of 10 most cited patents of Amgen:
| Publication Number | Citation Count |
| WO2009089004A1 | 2544 |
| US6660843B1 | 1019 |
| US6682736B1 | 940 |
| US20050053973A1 | 654 |
| US6673986B1 | 654 |
| US20050048512A1 | 590 |
| US20040175756A1 | 538 |
| WO2002066470A1 | 536 |
| US20050089932A1 | 510 |
| US6586398B1 | 479 |
Which Companies are using Amgen Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Amgen patent portfolio are Roche Holding Ag, Regeneron Pharmaceuticals Inc and Genentech.
List of the top forward citing Companies –
| Company | Number of Patents |
| Roche Holding Ag | 35 |
| Regeneron Pharmaceuticals Inc | 32 |
| Genentech | 22 |
| Abbvie Inc | 22 |
| Novartis | 21 |
| Hcr Collateral Management Llc | 21 |
| Merck Sharp & Dohme Corp | 16 |
| Onyx Therapeutics Inc | 15 |
| Biogen Ma Inc | 12 |
| Hanmi Science Co Ltd | 12 |
Count of 102 and 103 Type Rejections based on Amgen Patents
Top Amgen Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US7648702B2 | 25 |
| US8592562B2 | 21 |
| US6660843B1 | 19 |
| US10474162B2 | 16 |
| US20040248299A1 | 15 |
| US7705130B2 | 12 |
| US7459502B2 | 12 |
| US6541610B1 | 12 |
| US7829595B2 | 11 |
| US7288251B2 | 11 |
| US20130064825A1 | 11 |
| US6774106B2 | 10 |
| US20090317456A1 | 10 |
| US7737112B2 | 9 |
| US7498420B2 | 9 |
What Percentage of Amgen US Patent Applications were Granted?
Amgen (Excluding its subsidiaries) has filed 2454 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1296 have been granted leading to a grant rate of 70.05%.
Below are the key stats of Amgen’s patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Amgen?
| Law Firm | Total Applications | Success Rate |
| Amgen Inc | 960 | 72.91% |
| Marshall Gerstein & Borun Llp | 279 | 74.60% |
| Richard Aron Osman | 74 | 93.15% |
| Mcdonnell Boehnen Hulbert & Berghoff | 68 | 63.64% |
| Jones Day | 56 | 65.00% |
| Finnegan Henderson Farabow Garrett & Dunner | 50 | 47.83% |
| Kilpatrick Townsend & Stockton | 48 | 20.00% |
| Jones Day For Celgene Corporation | 45 | 95.56% |
| Foley & Lardner Llp | 25 | 55.56% |
| Banner & Witcoff | 22 | 81.82% |
EXCLUSIVE INSIGHTS COMING SOON!
What are Amgen’s key innovation segments?
What Technologies are Covered by Amgen?
The chart below distributes patents filed by Amgen in different countries on the basis of the technology protected in patents. It also represents the markets where Amgen thinks it’s important to protect particular technology inventions.
R&D Focus: How Amgen search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Amgen?
